Genelux Corporation Common Stock GNLX
i
Market datapartial · fetched 2026-11-07T02:14:44.477Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:46:38.889402943Z
FundamentalsAlpha Vantage · unavailable
Genelux Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 3.61 | 294.5% | 117.4% | 2.97 | 312.0% | 27.8% |
| 50Δ | 3.25 | 302.0% | 101.2% | 3.46 | 312.0% | 24.4% |
| 55Δ | 2.89 | 309.5% | 85.0% | 3.94 | 312.0% | 20.9% |
| 60Δ | 2.53 | 317.0% | 68.8% | 4.43 | 312.0% | 17.5% |
| 65Δ | 4.91 | 312.0% | 14.1% | |||
| 70Δ | 6.87 | 343.4% | 11.5% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 3.61
- IV
- 294.5%
- B/E move
- 117.4%
- Pseudo strike
- 2.97
- IV
- 312.0%
- B/E move
- 27.8%
50Δ
- Pseudo strike
- 3.25
- IV
- 302.0%
- B/E move
- 101.2%
- Pseudo strike
- 3.46
- IV
- 312.0%
- B/E move
- 24.4%
55Δ
- Pseudo strike
- 2.89
- IV
- 309.5%
- B/E move
- 85.0%
- Pseudo strike
- 3.94
- IV
- 312.0%
- B/E move
- 20.9%
60Δ
- Pseudo strike
- 2.53
- IV
- 317.0%
- B/E move
- 68.8%
- Pseudo strike
- 4.43
- IV
- 312.0%
- B/E move
- 17.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.91
- IV
- 312.0%
- B/E move
- 14.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.87
- IV
- 343.4%
- B/E move
- 11.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet…
More →GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is…
More →HELP
Description unavailable
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →